Oncology Clinic in Skopje faces shortage of Fesgo breast cancer therapy

Patients at the Clinic for Oncology in Skopje have been left without their scheduled Fesgo therapy. The clinic issued a public apology to the affected women, requesting patience and understanding, but failed to provide a specific date for when the medication will be available.

The facility attributed the delay to distribution and delivery issues, stating these factors are “outside the direct control of the Clinic.” While the administration acknowledged the importance of continuous treatment and stated they are taking measures within their jurisdiction to resolve the matter, they did not identify the cause of the standstill or an expected resolution time.

Fesgo is used to treat certain forms of HER2-positive breast cancer and contains the active substances pertuzumab and trastuzumab. This is not the first instance of supply issues; on October 8, Director Igor Stojkovski noted that minimal delays could occur due to distribution deficiencies and mentioned exploring three-year procurement plans for 2027. Patient associations, including Hema-Onco, have previously warned that ad hoc solutions do not ensure the necessary continuity of care.